Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial closure

IND.184 - A Phase II Study of Sunitinib, an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients with Unresectable, Locally Advanced or Metastatic Cervical Carcinoma is officially closed to accrual as of May 12, 2008.
http://www.ctg.queensu.ca/trials/ind/i184/184.html